Clinical trial
A Phase 1, Study of Nebulized Matrix - Allogeneic Human Amniotic Fluid (HAF) In Patients With Interstitial Lung Disease: AIRMID Trial
NCT07372989 is registered in ClinicalTrials.gov with Maule Stem Cell Research Institute, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Study of Nebulized Matrix - Allogeneic Human Amniotic Fluid (HAF) In Patients With Interstitial Lung Disease: AIRMID Trial
- Lead sponsor
- Maule Stem Cell Research Institute, Inc.
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- February 23, 2026
- Completion date
- October 31, 2028
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.